SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

Key Points

• Short interest fell 13.3% to 1,613,558 shares as of Feb. 27, equal to about 4.5% of the float and a short‑interest ratio of 5.7 days (avg. volume 281,424 shares).
• Analysts show a mixed view but a consensus of Moderate Buy with an average price target of $10 (ratings: 1 Strong Buy, 4 Buy, 2 Sell), with recent actions including UBS initiating coverage at Buy/$7 and Chardan raising its target to $14.
• SABS shares traded near $3.94 (market cap ~$200.7M; 52‑week range $1.00–$6.60) after reporting an EPS loss of ($0.46) vs. a consensus (−$0.16), and analysts forecast about −3.69 EPS for the fiscal year.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the target of a large decline in short interest in February. As of February 27th, there was short interest totaling 1,613,558 shares, a decline of 13.3% from the February 12th total of 1,860,014 shares. Based on an average trading volume of 281,424 shares, the short-interest ratio is currently 5.7 days. Approximately 4.5% of the company's stock are sold short. Approximately 4.5% of the company's stock are sold short. Based on an average trading volume of 281,424 shares, the short-interest ratio is currently 5.7 days.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Weiss Ratings reiterated a "sell (d)" rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. Wall Street Zen downgraded SAB Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. UBS Group assumed coverage on SAB Biotherapeutics in a report on Wednesday, January 7th. They set a "buy" rating and a $7.00 price target for the company. Chardan Capital increased their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, March 11th. Finally, HC Wainwright dropped their price target on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, SAB Biotherapeutics has a consensus rating of "Moderate Buy" and an average price target of $10.00.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ SABS opened at $3.94 on Tuesday. The business's 50-day simple moving average is $4.03 and its 200-day simple moving average is $3.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $6.60. The firm has a market cap of $200.74 million, a price-to-earnings ratio of -1.70 and a beta of 0.59.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.30). As a group, equities research analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Several large investors have recently modified their holdings of SABS. HB Wealth Management LLC acquired a new position in SAB Biotherapeutics in the 3rd quarter valued at $618,000. Dimensional Fund Advisors LP bought a new stake in SAB Biotherapeutics during the third quarter valued at about $32,000. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics during the third quarter valued at about $30,000. Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $40,000. Finally, Commodore Capital LP bought a new position in shares of SAB Biotherapeutics in the third quarter worth about $8,847,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.